18F-fluoro-ethyl-tyrosine (18F-FET) PET/CT as a potential new diagnostic tool in multiple myeloma : a preliminary study
| Autor: | Anna Jachalska, Norbert Grząśko, Artur Jurczyszyn, A. Czyż, Monika Olejniczak, Jarosław Czyż, Rita Łopatto, Bogdan Małkowski |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Bone disease lcsh:Medicine 03 medical and health sciences 0302 clinical medicine Active disease medicine Soft tissue mass Radiology Nuclear Medicine and imaging In patient 18F-FET Multiple myeloma Original Paper business.industry 18F-FDG PET/CT lcsh:R Complete remission medicine.disease multiple myeloma 030104 developmental biology Ethyl tyrosine Oncology Radiology business 030217 neurology & neurosurgery After treatment |
| Zdroj: | Contemporary Oncology, Vol 23, Iss 1, Pp 23-31 (2019) Contemporary Oncology |
| Popis: | Aim of the study The aim of this study was to analyse the diagnostic accuracy of "18F-fluoro-ethyl-tyrosine (18F-FET) PET/CT tracer in multiple myeloma. Material and methods The analysed group included: patients with newly diagnosed active myeloma (eight patients); in very good partial remission or complete remission (VGPR or CR) after treatment (nine patients); and with active disease after relapse (15 patients). Results In patients with newly diagnosed myeloma, 64 lesions were found using CT and 83 lesions using 18F-FET. In six patients, the number of lesions using CT and 18F-FET was the same, and two had more lesions with the 18F-FET than with the CT. Patients in VGPR or CR had no FET-positive lesions. Fourteen out of 15 patients with active relapsed myeloma had 47 FET-positive lesions, CT assessment of the same group showed 282 lesions. In one patient with relapse soft tissue mass was found with 18F-FET but not with CT. Conclusions 18F-FET can be a promising alternative to 18F-FDG PET/CT for myeloma-related bone disease diagnosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|